Skip to main content
. 2023 Jan 10;72(6):1709–1723. doi: 10.1007/s00262-022-03360-9

Table 2.

Overall ICI activity and efficacy

graphic file with name 262_2022_3360_Tab2_HTML.jpg

TTBR time-to-best response, DOR duration of response, PFS progression-free survival, OS overall survival, CI confidence interval, CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR overall response rate, DCB durable clinical benefit